Skip to main content
CMG Pharmaceutical Co., Ltd. logo

CMG Pharmaceutical Co., Ltd. — Investor Relations & Filings

Ticker · 058820 ISIN · KR7058820002 KO Manufacturing
Open in API
Filings indexed 165 across all filing types
Latest filing 2019-04-30 Regulatory Filings
Country KR South Korea
Listing KO 058820

About CMG Pharmaceutical Co., Ltd.

http://www.cmgpharma.co.kr

CMG Pharmaceutical Co., Ltd. is a pharmaceutical company specializing in the development of advanced drug delivery systems. The company's core competency is its Oral Thin Film (OTF), or Orally Dissolving Film (ODF), technology platform. This technology is used to develop improved new drugs, new formulations, and combination therapies designed to enhance patient convenience and efficacy. The company's portfolio includes prescription medications and general pharmaceuticals. As an affiliate of CHA Health Systems, CMG Pharmaceutical is actively engaged in research and development, managing a pipeline of drug candidates and conducting clinical trials.

Recent filings

Filing Released Lang Actions
소속부변경
Regulatory Filings Classification · 95% confidence The document is a short, structured announcement regarding a change in the company's market classification (from 'Mid-sized Enterprise' to 'Venture Enterprise') on the stock exchange. It does not fit into specific financial reporting categories like 10-K or IR, nor is it a report publication announcement. As it is a regulatory notification regarding company status, it falls under the general regulatory filings category.
2019-04-30 Korean
사업보고서 (2018.12)
Audit Report / Information Classification · 96% confidence The document is a comprehensive 'Audit Report' (감사보고서) for CMG Pharmaceutical Co., Ltd. for the fiscal year 2018. It includes the independent auditor's opinion, consolidated financial statements (Statement of Financial Position, Statement of Comprehensive Income, Statement of Changes in Equity, Statement of Cash Flows), and detailed notes to the financial statements. It is not an Annual Report (10-K) as it lacks the broader management discussion and analysis (MD&A) or business overview typically found in a full 10-K, and it is not an Earnings Release (ER) as it is a formal, audited financial document. Therefore, it is classified as an Audit Report. FY 2018
2019-04-01 Korean
정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled '정기주주총회결과' (Annual General Meeting Results) and provides a summary of the resolutions passed during the meeting held on March 29, 2019, including financial statement approval, dividend decisions, and director appointments. This falls directly under the definition of a Declaration of Voting Results & Voting Rights Announcement (DVA).
2019-03-29 Korean
금전대여결정
Capital/Financing Update Classification · 95% confidence The document is a regulatory filing from CMG Pharmaceutical regarding a 'Decision to Lend Money' (금전대여결정) to an affiliate, CHA Health Systems, Inc. This is a specific corporate disclosure regarding a financial transaction (lending) that does not fit into standard categories like earnings, dividends, or share issues. As it is a formal regulatory disclosure of a material corporate event, it falls under the 'Regulatory Filings' category.
2019-03-22 Korean
감사보고서제출
Report Publication Announcement Classification · 95% confidence The document is a formal announcement titled 'Audit Report Submission' (감사보고서 제출) filed by CMG Pharmaceutical. It provides a summary of the audit opinion, key financial data (assets, liabilities, equity, profit/loss), and auditor information. While it contains financial data, it is a regulatory filing announcing the completion and submission of the audit report to the exchange, rather than the full annual report (10-K) or a standalone audit report document. Under the provided rules, this fits the 'Report Publication Announcement' (RPA) category as it serves to notify the market of the report's availability.
2019-03-21 Korean
주주총회소집공고
AGM Information Classification · 98% confidence The document is a formal 'Notice of Annual General Meeting' (주주총회소집공고) for CMG Pharmaceutical. It contains the meeting agenda, details on voting procedures, director activity reports, and financial statements (balance sheets, etc.) to be approved by shareholders. This document is a standard proxy statement/notice package sent to shareholders to inform them of the upcoming meeting and solicit their votes on specific agenda items. In the context of the provided categories, this fits the definition of a Proxy Solicitation & Information Statement.
2019-03-13 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.